Recently, Jiangsu Hengrui Medicine announced that its subsidiary, Shandong Shengdi Medicine, received the "Drug Clinical Trial Approval Notice" for HRS-7156 tablets issued by the National Medical Products Administration , and will soon conduct clinical trials for the indication of heart failure .

HRS-7156 tablets are a Class 1 new drug independently developed by the company. Preclinical data show that HRS-7156 can significantly improve cardiac function and lesions. Currently, there are no similar drugs approved for marketing in China or abroad.

To date, the cumulative R&D investment in the HRS-7156 related projects is approximately RMB 37.6 million (unaudited).

It is worth noting that not long ago, Hengrui Medicine announced that its HRS-5765 tablets had been approved to conduct clinical trials, with the indication being heart failure.

This drug is classified as a Class 1 new drug. Preclinical data shows that HRS-5765 can significantly improve cardiac function and lesions. Currently, no similar drugs have been approved for marketing in China or abroad. To date, the cumulative R&D investment in the HRS-5765 tablet project is approximately RMB 13.8 million (unaudited).

In addition, Hengrui has also developed several new drugs in the field of heart failure, including Myosin inhibitors, GLP-1 agonists, and biologics .

HRS-1893 (also known as BHB-1893) is a highly selective small molecule inhibitor of myosin. It is currently undergoing a Phase III clinical trial (NCT07021976) in China for obstructive hypertrophic cardiomyopathy (oHCM), a Phase II clinical trial for non-obstructive hypertrophic cardiomyopathy (nHCM), and a Phase II clinical trial for heart failure with preserved ejection fraction. Globally, one clinical pharmacology study has been completed (the Australian bridging trial), and Phase III studies for symptomatic oHCM and nHCM are planned for 2026.

The GLP-1/GIP dual receptor agonist HRS9531 is currently undergoing a phase II clinical trial in obese patients with heart failure and preserved ejection fraction.

The oral small molecule GLP-1 receptor agonist HRS-7535 is also undergoing a phase II clinical trial in obese patients with heart failure accompanied by mildly reduced ejection fraction/preserved ejection fraction.

HRS-9057 has been initiated in a Phase II clinical trial to evaluate its efficacy and safety in patients with fluid retention due to heart failure.

In terms of biological agents, Hengrui Medicine's SHR-6934 received implied approval for clinical trials in 2024 for the treatment of heart failure.

SHR-4658 is expected to receive clinical approval in 2025 for the treatment of heart failure. Preclinical data show that SHR-4658 can significantly improve cardiac function in animals with heart failure and has a good safety profile.

https://news.yaozh.com/archive/47813.html